All In Biotech

Drug Trial Radar · NCT07352969

A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients

A Randomized, Double-blind, Placebo-controlled, Multicenter, 24 Months Treatment Duration, Dose Finding Study, to Evaluate Efficacy, Safety and Pharmacodynamics of IBI3016 in Mild to Moderate Hypertensive Patients

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 352 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

352

Actual

Start

Feb 5, 2026

Primary completion

Mar 27, 2029

Study completion Mar 27, 2029

Sponsor

Sponsor type
Industry
First posted
Jan 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety and tolerability of IBI3016 or placebo, given subcutaneously, every 3 or 6 months, at different dose levels in patients with mild to moderate hypertension

Conditions

  • Hypertension

Interventions

  • IBI3016Drug

    Solution of Injection

  • PlaceboOther

    0.9% sodium chloride saline solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in SBP by OBPMTime frame: From baseline through month 3

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Anzhen Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.